Uterine leiomyoma;A méh leiomyomája

Orvosi Hetilap

Volumn 151, Issue 42, 2010, Pages 1734-1741

  Csatlós, Éva ^a   Rigó Jr , János ^a   Szabó, István ^a   Nagy, Zsolt ^b   Joó, József Gábor ^a,c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NAGY GEN Diagnosztikai es Kutatasi Kft   (Hungary)

^c Hungarian Natural History   (Hungary)

Author keywords

hysterectomy; laparoscopic uterine artery occlusion (LUAO); MRI guided focused ultrasound (MRgFUS); myolysis; myomectomy; ultrasound diagnostics; uterine artery embolisation (UAE); uterine leiomyoma

Indexed keywords

ASOPRISNIL; MIFEPRISTONE; ANTINEOPLASTIC AGENT; ESTRANE DERIVATIVE; HORMONE ANTAGONIST; OXIME;

FEMALE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; HYSTERECTOMY; LAPAROSCOPIC SURGERY; LAPAROSCOPIC UTERINE ARTERY OCCLUSION; MENSTRUATION DISORDER; MYOMECTOMY; PELVIS PAIN SYNDROME; REPRODUCTIVE HEALTH; REVIEW; UTERINE ARTERY; UTERINE ARTERY EMBOLIZATION; UTERUS MYOMA; DIFFERENTIAL DIAGNOSIS; GENETICS; INCIDENCE; LAPAROSCOPY; LEIOMYOMA; PATHOPHYSIOLOGY; ULTRASOUND THERAPY; UTERINE NEOPLASMS;

ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; ESTRENES; FEMALE; HORMONE ANTAGONISTS; HUMANS; HYSTERECTOMY; INCIDENCE; LAPAROSCOPY; LEIOMYOMA; MIFEPRISTONE; OXIMES; ULTRASONIC THERAPY; UTERINE ARTERY; UTERINE NEOPLASMS;

EID: 77957727056     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2010.28977     Document Type: Review

References (48)

1. Okolo, S.: Incidence, aetiology and epidemiology of uterine fibroids. Best Pract. Res. Clin. Ob. Gyn., 2008, 22, 571-588.
2. Cramer, S. F., Patel, A.: The frequency of uterine leiomyomas. Am. J. Clin. Pathol., 1990, 94, 435-438.
3. Marshall, L. M., Spiegelman, D., Barbieri, R. L. és mtsai: Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet. Gynecol., 1997, 90, 967-973.
4. Al Hendy, A., Salama, S. A.: Ethnic distribution of estrogen receptor-alpha polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil. Steril., 2006, 86, 686-693.
5. Wei, J. J., Chiriboga, L., Arslan, A. A. és mtsai: Ethnic differences in expression of the dysregulated proteins in leiomyomata. Hum. Reprod., 2006, 21, 57-67.
6. Faerstein, E., Szklo, M., Rosenshein, N.: Risk factors for uterine leiomyoma: a practice-based case-controll study I. African-American heritage, reproductive history, body size and smoking. Am. J. Epidemiol., 2001, 153, 1-10.
7. Lumbiganon, P., Rugpao, S., Phandhu-fung, S. és mtsai: Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case-control study. Br. J. Obstet. Gynecol., 1996, 103, 909-914.
8. Hammoud, A. O., Asaad, R., Berman, J. és mtsai: Volume change of uterine myomas during pregnancy: do myomas really grow? J. Minim. Invas. Gynecol., 2006, 13, 386-390.
9. Chiaffarino, F., Parazzini, F., La Vecchia, C. és mtsai: Use of oral contraceptives and uterine fibroids: results from a case-control study. Br. J. Obstet. Gynecol., 1999, 106, 857-860.
10. Shikora, S. A., Niloff, J. M., Bistrian, B. R. és mtsai: Relationship between obesity and uterine leiomyomata. Nutrition, 1991, 7, 251-255.
11. Wise, L. A., Palmer, J. R., Spiegelman, D. és mtsai: Influence of body size and body fat distribution on risk of uterine leiomyomata in US black women. Epidemiology, 2005, 16, 346-354.
12. Gross, K. L., Panhuysen, C. I., Kleinman, M. S. és mtsai: Involvement of fumarate hydratase in nonsyndromic uterine leiomyomas: genetic linkage analysis and FISH studies. Genes. Chrom. Canc., 2004, 41, 183-190.
13. Luoto, R., Kaprio, J., Rutanen, E. M. és mtsai: Heritability and risk factors of uterine fibroids - the Finnish Twin Cohort Study. Maturitas, 2000, 37, 15-26.
14. Kiuru, M., Launonen, V., Hietala, M. és mtsai: Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. Am. J. Pathol., 2001, 159, 825-829.
15. Reed, W. B., Walker, R., Horowitz, R. és mtsai: Cutaneous leiomyomata with uterine leiomyomata. Acta Derm. Venerol., 1973, 53, 409-416.
16. Alam, N. A., Rowan, A. J., Wortham, N. C. és mtsai: Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer and fumarate hydratase deficiency. Hum. Mol. Genet., 2003, 12, 1241-1252.
17. Schoenberg Fejzo, M., Ashar, H. R., Krauter, K. S. és mtsai: Translocation breakpoints upstream of the HMGIC gene in uterine leiomyomata suggest dysregulation of this gene by a mechanism different from that lipomas. Genes Chrom. Canc., 1996, 17, 1-6.
18. Li, S., Chiang, T. C., Davis, G. R. és mtsai: Decreased expression of WNT7A mRNA is inversely associated with the expression of estrogen receptor-alpha in hum, an uterine leiomyoma. J. Clin. Endocrinol. Metab., 2001, 86, 454-457.
19. Linder, D., Gartler, S. M.: Glucose-6-phosphatase dehydrogenase mosiacism: utilization as cell marker in the study of leiomyomas. Science, 1965, 150, 67-69.
20. Fleischer, R.: Pathophysiology of fibroid disease: angiogenesis and regulation of smooth muscle proliferation. Best Pract. Clin. Obst. Gyn., 2008, 22, 603-614.
21. Papp Z.: A noi nemi szervek jó és rosszindulatú daganatai. In: A szülészet-nogyógyászat tankönyve. Szerk.: Papp Z. Semmelweis Kiadó, Budapest, 2007, 465-520.
22. Gupta, S., Jude, J., Manyonda, I.: Clinical presentation of fibroids. Best Pract. Res. Clin. Obst. Gyn., 2008, 22, 615-626.
23. Propst, A. M., Hill, J. A. 3rd: Anatomic factors associated with recurrent pregnancy loss. Semin. Reprod. Med., 2000, 18, 341-350.
24. Stewart, E. A., Nowak, R. A.: Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum. Reprod. Update, 1996, 2, 295-306.
25. Montague, A. C., Swartz, D. P., Woodruff, J. D.: Sarcoma arising in a leiomyoma of the uterus: factors influencing prognosis. Am. J. Obstet. Gynecol., 1965, 92, 421-427.
26. Fedele, L., Bianchi, S., Dorta, M. és mtsai: Transvaginal ultrasonography in the differential diagnosis of adenomyoma versus leiomyoma. Am. J. Obstet. Gynecol., 1992, 167, 603-606.
27. Ghai, S., Dheeraj, K., Benjamin, M. és mtsai: Uterine artery embolization for leiomyomas: pre-and postprocedural evaluation with US. Radiographics, 2005, 25, 1159-1172.
28. Okizuka, H., Sugimura, K., Takemori, M. és mtsai: MR detection of degenerating uterine leiomyomas. J. Comput. Assist. Tomogr., 1993, 17, 760-766.
29. Goto, A., Takeuchi, S., Sugimura, K. és mtsai: Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isoenzymes in the differential diagnosis of leiomyomsarcoma from degenerated leiomyoma of the uterus. Int. J. Gynecol. Cancer, 2002, 12, 354-361.
30. Casillas, J., Joseph, R. C., Guerra, J. J. Jr.: CT appearance of uterine leiomyomas. Radiographics, 1990, 10, 999-1007.
31. Outwater, E. K., Siegelman, E. S., Kim, B. és mtsai: Ovarian Brenner-tumors: MR imaging characteristics. Magn. Reson. Imaging, 1998, 16, 1147-1153.
32. Botsis, D., Kassanos, D., Antoniu, G. és mtsai: Adenomyoma and leiomyoma: differential diagnosis with transvaginal sonography. J. Clin. Ultrasound., 1998, 26, 21-25.
33. Kugligowska, E., Deeds, L., Lu, K.: Pelvic pain: overlooked and underdiagnosed gynecologic conditions. Radiographics, 2005, 25, 3-20.
34. Levy, B. S.: Modern management of uterine fibroids. Acta Obstet. Gynecol., 2008, 87, 812-823.
35. Eisinger, S. H., Meldrum, S., Fiscella, K. és mtsai: Low-dose mifepristone for uterine leiomyomata. Obstet. Gynecol., 2003, 101, 243-250.
36. Chen, W., Ohara, N., Wang, J. és mtsai: A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J. Clin. Endocrinol. Metab., 2006, 91, 1296-1304.
37. Chwalisz, K., Larsen, L., Mattia-Goldberg, C. és mtsai: A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil. Steril., 2007, 87, 1399-1412.
38. Friedman, A. J., Hoffman, D. I., Comite, F. és mtsai: Treatment of leiomyomata uteri with leuprolide acetate depot: A doubleblind, placebo-controlled multicenter study. Obstet. Gynecol., 1991, 77, 720-725.
39. Farquahar, C. M., Steiner, C. A: Hysterectomy rates in the United States 1990-1997. Obstet. Gynecol., 2002, 99, 229-234.
40. Luciano, A. A.: Myomectomy. Clin. Obstet. Gynecol., 2009, 52, 362-371.
41. Seracchioli, R., Rossi, S., Govoni, F. és mtsai: Fertility and obstetric outcome after laparoscopic myomectomy of large leiomyomata: a randomized comparison with abdominal myomectomy. Hum. Reprod., 2000, 15, 2663-2668.
42. Phillips, D. R., Nathanson, H. G., Milim, S. J. és mtsa: Laparoscopic leiomyoma coagulation. J. Am. Assoc. Gynecol., 1996, 3, S39.
43. Burbank, F., Hutchins, F. L. Jr.: Uterine artery occlusion by embolization or surgery for the treatment of fibroids: a unifying hypothesis-transient uterine ischaemia. J. Am. Assoc. Gynecol., 2000, 7, S1-S49.
44. Myers, E. R., Goodwin, S., Landow, W. és mtsai: Prospective data collection of a new procedure by a specialty society: The FIBROID registry. Obstet. Gynecol., 2005, 106, 44-51.
45. Volkers, N. A., Hehenkamp, W. J., Birnie, E. és mtsai: Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids; 2 years' outcome from the randomized EMMY trial. Am. J. Obstet. Gynecol., 2007, 196, 519. e1-519.e11.
46. Holub, Z., Jabor, A., Lukac, J. és mtsai: Midterm follow-up study of laparoscopic dissection of uterine vessels for surgical treatment of symptomatic fibroids. Surg. Endosc., 2004, 18, 1349-1353.
47. Stewart, E. A., Gedroyc, W. M., Tempany, C. M. és mtsai: Focused ultrasound treatment of uterine fibroid tumors: safety and feasibility of a noninvasive thermoablative technique. Am. J. Obstet. Gynecol., 2003, 189, 48-54.
48. Stewart, E. A., Rabinovici, J., Tempany, C. M. és mtsai: Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril, 2006, 85, 22-29.